Treatment Options After CAR T Therapy for Large B-Cell Lymphoma
The professor of medicine from Duke University School of Medicine discussed treatment approaches for after relapse on CAR T cell therapy or for patients who are ineligible for CAR T therapy.
Video Player is loading.
This content originally appeared on our sister site, OncLive.
Recent Videos
Rebecca Ahrens-Nicklas, MD, PhD, and Kiran Musunuru, MD, PhD, MPH, ML, MRA, on the Next Steps for Personalized Gene Editing
Roger Hajjar, MD, on Helping to Bring Preclinical Gene Therapy Research to First-In-Human Trials
Rebecca Ahrens-Nicklas, MD, PhD, and Kiran Musunuru, MD, PhD, MPH, ML, MRA, on Treating CPS1 Deficiency With Personalized Gene Editing
Nicholas Giovannone, PhD, on Using Bispecific Antibodies to Redose AAV Gene Therapy
Nathan Yozwiak, PhD, on Commercial Bottlenecks in Gene Therapy Development
Diana Bharucha-Goebel, MD, and Bakri Elsheikh, MBBS, FRCP, on Setting Realistic Goals for Long-Standing SMA
Diana Bharucha-Goebel, MD, and Bakri Elsheikh, MBBS, FRCP, on Considerations for Starting SMA Treatment
Diana Bharucha-Goebel, MD, and Bakri Elsheikh, MBBS, FRCP, on How New Therapies Are Changing SMA Care Guidelines
James Beck, PhD, on Illuminating Genetic Insights in Parkinson Disease Through PD GENEration
James Beck, PhD, on Expanding Access to Whole Genome Sequencing in Parkinson Research
